Skip to main content
. 2020 May 21;136(9):1091–1104. doi: 10.1182/blood.2020005125

Table 2.

hrombosis in Myeloma IX and XI trials, by site

Induction treatment received Venous thrombosis Arterial thrombosis Total
DVT below knee DVT above knee PE Other VTE Superficial thrombophlebitis Line-associated VTE PE or DVT (type unknown) Location of recent operation Stroke TIA Arterial thrombosis MI
No. % No. % No. % No. % No. % No. % No. % No. % No. % No. % No. % No. % No. %
Myeloma IX
 Transplant-eligible
  CVAD 23 14.5 22 13.8 35 22.0 9 5.7 1 0.6 59 37.1 10 6.3 NR 159 100
  CTD 22 20.4 26 24.1 45 41.7 3 2.8 1 0.9 2 1.9 9 8.3 NR 108 100
  Total 45 16.9 48 18.0 80 30.0 12 4.5 2 0.7 61 22.8 19 7.1 NR 267 100
 Transplant-ineligible
  MP 2 11.1 10 55.6 6 33.3 0 0.0 0 0.0 0 0.0 0 0.0 NR 18 100
  CTDa 22 26.5 15 18.1 39 47.0 1 1.2 0 0.0 0 0.0 6 7.2 NR 83 100
  Total 24 23.8 25 24.8 45 44.6 1 1.0 0 0.0 0 0.0 6 5.9 NR 101 100
Total 69 18.8 73 19.8 125 34.0 13 3.5 2 0.5 61 16.6 25 6.8 NR 368 100
Myeloma XI
 Transplant-eligible
  CTD 37 20.8 39 21.9 78 43.8 7 3.9 1 0.6 1 0.6 NR 0 0.0 8 4.5 3 1.7 2 1.1 2 1.1 178 100
  CRD 49 28.2 51 29.3 51 29.3 9 5.2 1 0.6 0 0.0 NR 1 0.6 6 3.4 3 1.7 1 0.6 2 1.1 174 100
  KCRD 37 30.1 28 22.8 26 21.1 18 14.6 1 0.8 3 2.4 NR 1 0.8 3 2.4 3 2.4 1 0.8 2 1.6 123 100
  Total 123 25.9 118 24.8 155 32.6 34 7.2 3 0.6 4 0.8 NR 2 0.4 17 3.6 9 1.9 4 0.8 6 1.3 475 100
 Transplant-ineligible
  CTDa 25 19.7 30 23.6 44 34.6 11 8.7 0 0.0 0 0.0 NR 1 0.8 8 6.3 7 5.5 0 0.0 1 0.8 127 100
  CRDa 29 20.1 22 15.3 44 30.6 20 13.9 0 0.0 0 0.0 NR 0 0.0 18 12.5 8 5.6 1 0.7 2 1.4 144 100
  Total 54 19.9 52 19.2 88 32.5 31 11.4 0 0.0 0 0.0 NR 1 0.4 26 9.6 15 5.5 1 0.4 3 1.1 271 100
Total 177 23.7 170 22.8 243 32.6 65 8.7 3 0.4 4 0.5 NR 3 0.4 43 5.8 24 3.2 5 0.7 9 1.2 746 100

MI, myocardial infarction; NR, not recorded; PE, pulmonary embolism; TIA, transient ischemic attack.